# Test Results: literature/paper-summary.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-23.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** literature/paper-summary.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-23
- **Tester:** cross-model-harness
- **Assembly strategy:** concat
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
```
Context: I am a {RESEARCHER_ROLE} reviewing literature on {RESEARCH_TOPIC}. I need a structured summary of the following paper for my literature notes.

Paper text:
{PAPER_TEXT}

Task: Summarize this paper using the following structure.

1. **Citation**: Format as: Authors (Year). Title. Journal.

2. **Central Finding**: One to two sentences stating the main result or conclusion. Be specific about what was found, not just what was studied.

3. **Research Question/Hypothesis**: What question did the authors set out to answer?

4. **Methods Overview**:
   - Study system/organism
   - Key techniques or approaches
   - Sample size and design (if applicable)

5. **Key Results**: Three to five bullet points of specific findings. Include effect sizes or quantitative results where available.

6. **Limitations**: What limitations do the authors acknowledge? What limitations are apparent but not discussed?

7. **Open Questions**: What questions remain unanswered? What would logical next steps be?

8. **Relevance to My Work**: How might this paper inform {SPECIFIC_ASPECT_OF_YOUR_RESEARCH}?

Constraints:
- Use only information present in the paper—do not add context from other sources
- If a section cannot be completed from the available text, state "Not available in provided text"
- Distinguish between what authors claim and what the data support
- Note if sample sizes or effect sizes are not reported

Output format: Use the numbered structure above with headers in bold.

Context: I am a microbiome researcher reviewing literature on diet-microbiome interactions. I need a structured summary of the following paper for my literature notes.

Paper text:
[SIMULATED PAPER EXCERPT]

Title: Short-chain fatty acid production is reduced in patients with irritable bowel syndrome and correlates with symptom severity

Authors: Chen Y, Roberts K, Nakamura T, Wilson D, et al.

Abstract: Background: Irritable bowel syndrome (IBS) affects 10-15% of the global population, but its etiology remains unclear. Gut microbiome alterations have been implicated, yet functional consequences are understudied. We investigated short-chain fatty acid (SCFA) production in IBS patients versus healthy controls.

Methods: We recruited 45 IBS patients (Rome IV criteria) and 40 age- and sex-matched healthy controls. Fecal samples were analyzed using 16S rRNA gene sequencing (V4 region, Illumina MiSeq) and gas chromatography for SCFA quantification. Symptom severity was assessed using the IBS Severity Scoring System (IBS-SSS).

Results: IBS patients showed significantly reduced fecal butyrate (p=0.003) and propionate (p=0.02) compared to controls, while acetate levels were similar. Butyrate concentration negatively correlated with IBS-SSS scores (r=-0.42, p=0.004). Patients with IBS showed depletion of Faecalibacterium prausnitzii and Roseburia species, both known butyrate producers. No significant differences were observed in alpha diversity metrics (Shannon, observed ASVs).

Discussion: Our findings suggest that reduced SCFA production, particularly butyrate, may contribute to IBS symptoms. The correlation with symptom severity supports a functional role for these metabolites. Limitations include the cross-sectional design, which cannot establish causality, and recruitment from a single clinical center. Future longitudinal studies and intervention trials targeting SCFA production are warranted.

Relevance aspect: how microbial metabolites affect gut health in my mouse models

**Constraints:**
- Use only information present in the paper—do not add context from other sources
- If a section cannot be completed from the available text, state "Not available in provided text"
- Distinguish between what authors claim and what the data support
- Note if sample sizes or effect sizes are not reported
```

## Model Output
```


**1. Citation**: Not available in provided text  

**2. Central Finding**: IBS patients have significantly lower fecal butyrate and propionate levels than healthy controls, and reduced butyrate concentration correlates with higher symptom severity as measured by the IBS‑Severity Scoring System.  

**3. Research Question/Hypothesis**: The authors aimed to determine whether short‑chain fatty acid (SCFA) production differs between IBS patients and healthy controls and whether SCFA levels are associated with IBS symptom severity.  

**4. Methods Overview**:  
- **Study system/organism**: Human fecal samples from IBS patients (diagnosed per Rome IV criteria) and age‑ and sex‑matched healthy controls.  
- **Key techniques or approaches**: 16S rRNA gene sequencing (V4 region, Illumina MiSeq) for microbial community profiling; gas chromatography for quantification of fecal SCFAs (acetate, propionate, butyrate); IBS Severity Scoring System (IBS‑SSS) to assess symptom severity.  
- **Sample size and design**: 45 IBS patients and 40 healthy controls; cross‑sectional comparative design.  

**5. Key Results**:  
- Fecal butyrate was significantly reduced in IBS patients versus controls (p = 0.003).  
- Fecal propionate was significantly reduced in IBS patients versus controls (p = 0.02).  
- Acetate levels did not differ significantly between groups (reported as similar; exact p‑value not provided).  
- Butyrate concentration negatively correlated with IBS‑SSS scores (r = ‑0.42, p = 0.004).  
- IBS patients showed depletion of *Faecalibacterium prausnitzii* and *Roseburia* species, known butyrate producers.  
- No significant differences in alpha diversity (Shannon index, observed ASVs) between groups.  

**6. Limitations**:  
- Authors acknowledge the cross‑sectional design precludes inference of causality.  
- Recruitment was limited to a single clinical center, potentially limiting generalizability.  
- Apparent limitations not discussed: lack of data on diet, medication use, or other confounders; relatively modest sample size; no functional metagenomic or metabolomic validation of SCFA production pathways; no intervention to test whether restoring SCFAs alleviates symptoms.  

**7. Open Questions**:  
- Does reduced SCFA production directly cause IBS symptoms, or is it a consequence of altered gut physiology or microbiota?  
- Can increasing SCFA levels (e.g., via prebiotics, probiotics, or direct supplementation) improve symptom severity in IBS?  
- Are the observed depletions of *F. prausnitzii* and *Roseburia* causally linked to the SCFA deficit?  
- How do longitudinal changes in SCFA levels relate to fluctuations in symptom severity over time?  

**8. Relevance to My Work**: The study indicates that fecal SCFA concentrations, especially butyrate, serve as a functional biomarker linked to gut health and symptom severity in humans. In my mouse models, measuring SCFA levels could provide a comparable readout of mucosal health, and interventions aimed at boosting butyrate‑producing microbes may be worthwhile to test for amelioration of IBS‑like phenotypes.
```

## Assessment

_Machine-suggested (UNCONFIRMED) — drafted by Claude Opus 4.7 on 2026-06-24 to speed T4 review. An author must independently read the Model Output above and set the real Recommendation. Anything labeled here is triage, not domain expert review._

**Machine triage:** Compact 8-section summary (31 lines). All stats accurate. Marks Citation field as 'Not available in provided text' (more strictly following the constraint than Sonnet/Opus/GPT-5.5 which still listed the authors and title). Hits all key results.

**Suggested verdict (UNCONFIRMED):** Pass with notes

**What still needs human verification:**
- Marking the whole Citation field as 'Not available' may be overly strict — the authors and title ARE in the provided text; only journal and year are missing. The other models partially completed the citation.
- Cross-model: see Sonnet cell.

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
